Literature DB >> 3028475

Mass action analysis of kinetics and extent of fusion between Sendai virus and phospholipid vesicles.

S Nir, K Klappe, D Hoekstra.   

Abstract

The kinetics and extent of fusion between Sendai virus particles and liposomes were investigated with an assay for lipid mixing based on the relief of self-quenching of fluorescence. The measurements, which were carried out at pH 7.4 and 5.0, included liposomes of three compositions, cardiolipin (CL), CL/dioleoylphosphatidylcholine (CL/DOPC 1:1), and phosphatidylserine (PS). Liposomal lipid concentrations varied from 2.5 to 50 microM. In addition, the effect of low concentrations of the dehydrating agent poly(ethylene glycol) (PEG) on fusion between the virus and the liposomes at pH 7.4 was studied. The results were analyzed in terms of a mass action kinetic model which views the overall fusion reaction as a sequence of a second-order process of virus-liposome adhesion or aggregation, followed by the first-order fusion reaction itself. The fusion products were shown to consist of a single virus particle and several liposomes. Analytical solutions were found for the final extent of fusion and increase in fluorescence intensity following the fusion of fluorescently labeled virus particles with liposomes. The final extents of fluorescence intensity were explained by assuming an essentially irreversible binding of liposomes to inactive virus particles. The percents of active virus particles and the rate constants of fusion and aggregation were larger at pH 5 than at pH 7.4, increased when PEG was included in the medium, and varied with liposomal lipid composition according to the sequence CL greater than CL/DOPC greater than PS.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3028475     DOI: 10.1021/bi00373a020

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  10 in total

1.  Fusion between retinal rod outer segment membranes and model membranes: functional assays and role for peripherin/rds.

Authors:  K Boesze-Battaglia
Journal:  Methods Enzymol       Date:  2000       Impact factor: 1.600

2.  The human fibroblast receptor for gp86 of human cytomegalovirus is a phosphorylated glycoprotein.

Authors:  S Keay; B Baldwin
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

3.  Kinetics of influenza virus fusion with the endosomal and plasma membranes of cultured cells. Effect of temperature.

Authors:  I Nunes-Correia; S Nir; M C Pedroso de Lima
Journal:  J Membr Biol       Date:  2003-09-01       Impact factor: 1.843

Review 4.  Membrane fusion of enveloped viruses: especially a matter of proteins.

Authors:  D Hoekstra
Journal:  J Bioenerg Biomembr       Date:  1990-04       Impact factor: 2.945

5.  General analysis of receptor-mediated viral attachment to cell surfaces.

Authors:  T J Wickham; R R Granados; H A Wood; D A Hammer; M L Shuler
Journal:  Biophys J       Date:  1990-12       Impact factor: 4.033

6.  Mass action kinetics of virus-cell aggregation and fusion.

Authors:  J Bentz; S Nir; D G Covell
Journal:  Biophys J       Date:  1988-09       Impact factor: 4.033

7.  Fusion between Newcastle disease virus and erythrocyte ghosts using octadecyl Rhodamine B fluorescence assay produces dequenching curves that fit the sum of two exponentials.

Authors:  C Cobaleda; A García-Sastre; E Villar
Journal:  Biochem J       Date:  1994-06-01       Impact factor: 3.857

8.  Fusion of enveloped viruses with cells and liposomes. Activity and inactivation.

Authors:  S Nir; N Düzgünes; M C de Lima; D Hoekstra
Journal:  Cell Biophys       Date:  1990-10

9.  Anti-idiotype antibodies that mimic gp86 of human cytomegalovirus inhibit viral fusion but not attachment.

Authors:  S Keay; B Baldwin
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

10.  Membrane destabilization by N-terminal peptides of viral envelope proteins.

Authors:  N Düzgüneş; S A Shavnin
Journal:  J Membr Biol       Date:  1992-05       Impact factor: 1.843

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.